Vaccine 2008,26(Suppl 10):K53-K61.CrossRef 4. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG: Identification and Selonsertib characterization

of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673–682.CrossRef 5. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S: Lethal effect of the anti-Fas antibody in mice. Nature 1993, 364:806–809.CrossRef 6. Nagata S: Apoptosis by death factor. Cell 1997, 88:355–365.CrossRef 7. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, selleck chemicals Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104:155–162.CrossRef 8. Walczak H, Miller RE, Ariail K, Gliniak Ivacaftor in vitro B,

Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999, 5:157–163.CrossRef 9. Folkman J: Tumor angiogenesis: therapeutic implications. New Engl J Med 1971, 285:1182–1186.CrossRef 10. Folkman J: Tumor angiogenesis and tissue factor. Nat Med 1996, 2:167–168.CrossRef 11. Auerbach W, Auerbach R: Angiogenesis inhibition: a review. Pharmacol Therapeut 1994, 63:265–311.CrossRef 12. Winlaw DS: Angiogenesis in the pathobiology and treatment of vascular and malignant diseases. Ann Thorac Surg 1997, 64:1204–1211.CrossRef 13. Folkman J: Is

angiogenesis an organizing principle in biology and medicine? J Pediatr Surg 2007, 42:1–11.CrossRef 14. Folkman J: Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 2006, 312:594–607.CrossRef 15. Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007, 6:273–286.CrossRef 16. Michael SO: Antiangiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer. crotamiton Int J Radiat Oncol Biol Phys 2007, 69:S64-S66. 17. Zhuang HQ, Yuan ZY: Process in the mechanisms of endostatin combined with radiotherapy. Cancer Lett 2009,282(1):9–13.CrossRef 18. Herbst RS, Lee AT, Tran HT, Abbruzzese JL: Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. Curr Oncol Rep 2001, 3:131–140.CrossRef 19. Jia Y, Liu M, Cao L, Zhao X, Wu J, Lu F, Li Y, He Y, Ren S, Ju Y, Wang Y, Li Z: Recombinant human endostatin, Endostar, enhances the effects of chemo-radiotherapy in a mouse cervical cancer xenograft model. Eur J Gynaecol Oncol 2011,32(3):316–324. 20.